From MarketBeat:

Catalent, Inc. (NYSE:CTLT) has an average rating of “Hold” from twelve analysts, with a $50.45 target price. Barclays, Royal Bank of Canada, and William Blair have issued key reports on the stock. Hedge funds such as KB Financial Partners LLC and Covestor Ltd have increased their stakes in the company. Catalent stock is down 0.5%, trading at $50.09.

Catalent reported ($0.10) earnings per share. The company topped consensus estimates, with an estimated 0.53 earnings per share for the fiscal year. Catalent develops solutions for drugs, biologics, cell and gene therapies, and consumer health products.

MarketBeat, a narrative science and financial data provider, has released an accurate report on Catalent. Potential investors can view a free report for the top-ranked research analysts’ recommendations. Catalent is currently recommended as a “Hold” but top-rated analysts believe there are better investments.



Read more: Catalent, Inc. (NYSE:CTLT) Receives Average Recommendation of “Hold” from Analysts